Edit
Proteon Therapeutics
https://www.proteontherapeutics.com/Last activity: 29.06.2016
Active - Reference to Protara
Engaged in the development of novel pharmaceuticals for renal and vascular disease.
Location: United States, Massachusetts, Waltham
Total raised: $45M
Investors 1
| Date | Name | Website |
| - | Omega Fund... | omegafunds... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.05.2014 | Series D | $45M | - |
Mentions in press and media 13
| Date | Title | Description |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 01.04.2015 | Top tips for healthcare startups to protect their intellectual property | Franano, who has led the intellectual property strategy at all three of his companies, shared some advice about how entrepreneurs can protect their intellectual property in a cost-effective way. The interview was edited for length and clari... |
| 18.02.2015 | Bessemer Looks Forward With New $1.6B Fund | Bessemer Venture Partners (BVP) announced its latest investment fund today with $1.6B in investments. It has dubbed it BVP IX. It follows a highly successful BVP VIII. Byron Deeter, a partner at BVP says this is just part of the normal fund... |
| 22.01.2015 | Bessemer Venture Partners 2014 Results Include 21 Exits, and Three IPOs | But They Don’t Always Get it Right: Established VC Kicks off 2015 by Updating List of Most Painful Misses MENLO PARK, Calif.–(BUSINESS WIRE)–January 22, 2015– Bessemer Venture Partners (BVP) – a global venture capital firm backing great ent... |
| 30.10.2014 | TVM Capital Life Science counts two successful biotech IPOs of portfolio in one week; Bristol- Myers Squibb Entered into Agreement that Provides an Exclusive Option to Acquire F-star Alpha Ltd. | TVM Capital Life Science counts two successful biotech IPOs of portfolio in one week: Proteon Therapeutics, Inc, Waltham, USA and Probiodrug AG, Halle, Germany. Additionally, Bristol- Myers Squibb Entered into Agreement that Provides an Exc... |
| 16.05.2014 | Proteon Therapeutics Raises $45M in Series D Equity Financing | Proteon Therapeutics Inc., a Waltham, Mass.-based biopharmaceutical company developing pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases, raised $45m in Series D equity financing. This inclu... |
| 16.05.2014 | Proteon Therapeutics Lands $45M of Series D | WALTHAM, MA, Privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases, announced today $45 million of Series D. >>... |
| 14.05.2014 | Proteon Therapeutics Announces Publication of Results from Phase 2 Study of PRT-201 | -Data in Journal of Vascular Surgery Demonstrate Potential to Improve Function and Durability of Vascular Access Required for Hemodialysis- WALTHAM, Mass. – May 14, 2014 – Proteon Therapeutics Inc., a privately held biopharmaceutical compa... |
| 12.08.2011 | Proteon Therapeutics Raises $15.2M | Previous investors include Bessemer Venture Partners, Devon Park Bioventures, MPM Bio IV NVS Strategic Fund LP, Vectis Healthcare and Life Sciences Fund, TVM Capital, Skyline Ventures, Prism VentureWorks, Intersouth Partners and several a... |
| 24.09.2007 | Alnylam and Merck Go Their Separate Ways, TransMedics Files to Go Public, ZipCar Reservation System Ready to Go Anywhere, and More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Another week, another giant inbox full of news. Here are the highlights. —Not long after closing one of New England’s 10 biggest second-quarter venture deals, Andover-based Tr... |
Show more